X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs CIPLA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD CIPLA BIOCON LTD/
CIPLA
 
P/E (TTM) x 36.6 44.1 83.0% View Chart
P/BV x 4.9 3.6 133.9% View Chart
Dividend Yield % 1.5 0.4 430.3%  

Financials

 BIOCON LTD   CIPLA
EQUITY SHARE DATA
    BIOCON LTD
Mar-16
CIPLA
Mar-17
BIOCON LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs496622 79.7%   
Low Rs397458 86.5%   
Sales per share (Unadj.) Rs174.3181.9 95.8%  
Earnings per share (Unadj.) Rs44.812.9 348.1%  
Cash flow per share (Unadj.) Rs56.929.3 194.2%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %1.10.4 302.7%  
Book value per share (Unadj.) Rs202.8155.7 130.2%  
Shares outstanding (eoy) m200.00804.51 24.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.63.0 86.2%   
Avg P/E ratio x10.042.0 23.7%  
P/CF ratio (eoy) x7.818.4 42.5%  
Price / Book Value ratio x2.23.5 63.4%  
Dividend payout %11.215.5 71.8%   
Avg Mkt Cap Rs m89,220434,516 20.5%   
No. of employees `0004.423.0 19.2%   
Total wages/salary Rs m6,36326,338 24.2%   
Avg. sales/employee Rs Th7,894.56,349.1 124.3%   
Avg. wages/employee Rs Th1,441.21,143.0 126.1%   
Avg. net profit/employee Rs Th2,029.7449.3 451.7%   
INCOME DATA
Net Sales Rs m34,854146,302 23.8%  
Other income Rs m8452,287 36.9%   
Total revenues Rs m35,699148,589 24.0%   
Gross profit Rs m8,20024,758 33.1%  
Depreciation Rs m2,42313,229 18.3%   
Interest Rs m1021,594 6.4%   
Profit before tax Rs m6,52012,222 53.3%   
Minority Interest Rs m-7440-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m5,7540-   
Tax Rs m2,5691,798 142.9%   
Profit after tax Rs m8,96110,354 86.5%  
Gross profit margin %23.516.9 139.0%  
Effective tax rate %39.414.7 267.9%   
Net profit margin %25.77.1 363.3%  
BALANCE SHEET DATA
Current assets Rs m39,93287,370 45.7%   
Current liabilities Rs m16,27633,081 49.2%   
Net working cap to sales %67.937.1 182.9%  
Current ratio x2.52.6 92.9%  
Inventory Days Days5487 61.6%  
Debtors Days Days8662 138.3%  
Net fixed assets Rs m39,101111,567 35.0%   
Share capital Rs m1,0001,609 62.2%   
"Free" reserves Rs m38,591123,645 31.2%   
Net worth Rs m40,556125,254 32.4%   
Long term debt Rs m20,72436,454 56.9%   
Total assets Rs m84,816209,532 40.5%  
Interest coverage x64.98.7 749.0%   
Debt to equity ratio x0.50.3 175.6%  
Sales to assets ratio x0.40.7 58.9%   
Return on assets %10.75.7 187.4%  
Return on equity %22.18.3 267.3%  
Return on capital %19.08.5 223.3%  
Exports to sales %30.734.2 89.9%   
Imports to sales %20.48.3 244.4%   
Exports (fob) Rs m10,71750,050 21.4%   
Imports (cif) Rs m7,10512,203 58.2%   
Fx inflow Rs m11,78951,066 23.1%   
Fx outflow Rs m8,39317,678 47.5%   
Net fx Rs m3,39633,388 10.2%   
CASH FLOW
From Operations Rs m5,26423,824 22.1%  
From Investments Rs m-9,540-13,127 72.7%  
From Financial Activity Rs m10,867-13,239 -82.1%  
Net Cashflow Rs m6,591-2,478 -266.0%  

Share Holding

Indian Promoters % 40.4 16.0 252.5%  
Foreign collaborators % 20.6 20.8 99.0%  
Indian inst/Mut Fund % 8.4 12.2 68.9%  
FIIs % 10.7 23.7 45.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 19.9 26.2 76.0%  
Shareholders   109,995 161,166 68.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 18, 2017 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - JUBILANT LIFE SCIENCES COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS